ArticleOsteoarthritis and cartilage open2026
Analysis of disease burden of osteoarthritis in China from 1990 to 2021 and projections for 2022-2044.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the secular trend of osteoarthritis (OA) disease burden in China from 1990 to 2021 and predict future burden changes spanning 2022-2044 to support targeted public health intervention. Methods: Based on the Global Burden of Disease 2021 (supplemented with partial 2023 GBD data), crude incidence, age-standardized incidence rate (ASIR), disability-adjusted life years (DALYs) and OA prevalence data were retrieved. Joinpoint regression calculated average annual percentage change (AAPC) to assess secular trends; ARIMA and Brown time-series models were selected via AIC and residual diagnosis for future burden prediction, with 95% forecast uncertainty intervals calculated. Results: National OA prevalent cases increased from 4.65 million in 1990 to 11.65 million in 2021, with the AAPC of ASIR and age-standardized DALY rate reaching 0.43% and 0.49% (all P < 0.001). China's ASIR surpassed the global average after 2003; females sustained higher OA burden than males, incidence peaked among people aged 55-59 years, and DALY loss predominantly clustered in the population ≥85 years. Knee OA dominated the burden across all anatomical subtypes. Forecasts indicate the national ASIR and standardized DALY rate will rise to 589.00/100,000 and 292.02/100,000 by 2044 with inherent predictive uncertainty. Conclusion: China's overall OA burden has risen substantially and will keep increasing over the next two decades. Females, middle-aged and elderly residents, and patients with knee OA constitute core high-risk groups. These findings provide reliable epidemiological evidence for hierarchical OA prevention and national health policy formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.